|
|
|
| The Value of ADC of DWI Sequence in Differentiating Benign and Malignant Focal Lesions of Prostate |
| WANG Kai, ZHANG Qianwen, ZHANG Peng |
| Chaohu Hospital,Anhui Medical University, Anhui Chaohu 238000, China |
|
|
|
|
Abstract Objective: To investigate the value of apparent diffusion coefficient (ADC) of diffusion weighted imaging (DWI) sequence in differentiating benign and malignant focal lesions of the prostate. Methods: A total of 105 patients with peripheral zone lesions of prostate treated in our hospital from January 2019 to November 2022 were selected,including 59 patients with malignant lesions and 46 patients with benign lesions.The difference of ADC values between benign and malignant lesions was analyzed,and the relationship between ADC values and clinicopathology of malignant lesions was analyzed. Results: The ADC value of malignant lesions was (0.81±0.13) × 10-3 mm2/s,which was lower than that of benign lesions (P<0.05).The ADC value of middle and high risk lesions was (0.75±0.16)×10-3 mm2/s,which was lower than low-risk lesions (P<0.05).The ADC values of the lesions in clinical stage C and D were (0.76± 0.15) ×10-3 mm2/s and (0.72±0.14)×10-3 mm2/s,which was lower than that of stage B lesions (P<0.05).There was no significant difference in ADC values among different age,body mass index,lesion diameter and pathological type groups (P>0.05).The ADC value of malignant lesions was negatively correlated with Gleason score (r=-0.343,P<0.05).The area under the ROC curve of malignant lesions judged by ADC value was 0.912 (95% CI:0.839~0.986),P<0.05,and the cut-off value was 0.99×10-3 mm2/s,the sensitivity and specificity were 86.10% and 92.80%,respectively. Conclusion: The ADC value of DWI sequence has a high diagnostic value in differentiating benign and malignant focal lesions around the prostate,and the ADC value is related to the severity and clinical stage.
|
|
|
|
|
|
[1] Sandhu S,Moore CM,Chiong E,et al.Prostate cancer[J].Lancet,2021,398 (10305):1075-1090.
[2] Fenner A.Prostate cancer:highlights from research[J].Nature,2022,609 (7927):32-33.
[3] Hugosson J,Mansson M,Wallstrom J,et al.Prostate cancer screening with PSA and MRI followed by targeted biopsy only[J].N Engl Med,2022,387(23):2126-2137.
[4] Eklund M,Jaderling F,Discacciati A,et al.MRI-targeted or standard biopsy in prostate cancer screening[J].N Engl Med,2021,385 (10):908-920.
[5] Hu L,Wei L,Wang S,et al.Better lesion conspicuity translates into improved prostate cancer detection:comparison of non-parallel-transmission-zoomed-DWI with conventional-DWI[J].Abdom Radiol (NY),2021,46 (12):5659-5668.
[6] Bulten W,Kartasalo K,Chen PC,et al.Artificial intelligence for diagnosis and Gleason grading of prostate cancer:the PANDA challenge[J].Nat Med,2022,28 (1):154-163.
[7] Arap W,Pasqualini R,Costello JF.Prostate cancer progression and the epigenome[J].N Engl Med,2020,383(23):2287-2290.
[8] Ghai S,Perlis N,Atallah C,et al.Comparison of micro-US and multiparametric MRI for prostate cancer detection in biopsy-naive men[J].Radiology,2022,305 (2):390-398.
[9] Lee GH,Chatterjee A,Karademir I,et al.Comparing radiologist performance in diagnosing clinically significant prostate cancer with multiparametric versus hybrid multidimensional MRI[J].Radiology,2022,305 (2):399-407.
[10] 黄辉,田维云,庞佑菊,等.2型5a还原酶抑制剂和a1A受体阻滞剂对良性前列腺增生患者尿道角影响价值的研究[J].成都医学院学报,2021,16(5):625-628,632.
[11] 王利伟,王峰,殷信道,等.68Ga-PSMA-11 PET/CT显像SUVmax联合MRI ADC诊断前列腺癌的价值[J].中华核医学与分子影像杂志,2019,39(5):257-261.
[12] Thomsen FB,Westerberg M,Garmo H,et al.Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade:Nationwide,population-based register study[J].PLoS One,2020,15 (1):228447. |
|
|
|
2023, Vol. 29 
